Avidity Biosciences, Inc - Asset Resilience Ratio
Avidity Biosciences, Inc (RNAM) has an Asset Resilience Ratio of 67.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Avidity Biosciences, Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Avidity Biosciences, Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Avidity Biosciences, Inc's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Avidity Biosciences, Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read RNAM liabilities breakdown for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $1.31 Billion | 67.13% |
| Total Liquid Assets | $1.31 Billion | 67.13% |
Asset Resilience Insights
- Very High Liquidity: Avidity Biosciences, Inc maintains exceptional liquid asset reserves at 67.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Avidity Biosciences, Inc Industry Peers by Asset Resilience Ratio
Compare Avidity Biosciences, Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Avidity Biosciences, Inc (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Avidity Biosciences, Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 67.13% | $1.31 Billion | $1.96 Billion | -14.83pp |
| 2024-12-31 | 81.95% | $1.28 Billion | $1.56 Billion | +16.68pp |
| 2023-12-31 | 65.27% | $410.27 Million | $628.55 Million | +22.95pp |
| 2022-12-31 | 42.32% | $270.33 Million | $638.80 Million | +22.42pp |
| 2021-12-31 | 19.90% | $85.09 Million | $427.58 Million | +17.90pp |
| 2020-12-31 | 2.00% | $6.68 Million | $333.90 Million | -- |
About Avidity Biosciences, Inc
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics called antibody oligonucleotide conjugates (AOCs). Its AOC platform is designed to combine the specificity of monoclonal antibodies with the precision of RNA therapeutics to target the root cause of diseases previously untreatable with such therapeutics. The company's pipeline has three programs in… Read more